Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Consumer Discretionary Select Sector SPDR Fund (XLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Consumer Discretionary Select Sector SPDR Fund — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $279.77 (market cap $39.89B), while Consumer Discretionary Select Sector SPDR Fund trades at $116.78. The key difference: Consumer Discretionary Select Sector SPDR Fund is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | XLY | |
|---|---|---|
Market Cap | $39.89B | — |
Sector | Health | — |
52-Week High | $491.22 | $124.52 |
52-Week Low | $278.09 | $105.64 |
Enterprise Value | $38.15B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
XLY trades at $117.24, up 0.33% today, with neutral technical signals from oscillators and a bearish moving average trend. Support levels are at $115 and $114, while resistance sits near $118. Analyst consensus is unanimously bullish with a 100% buy rating. Recent news highlights consumer discretionary sector strength amid inflation pressures and holiday spending trends.
The outlook for XLY is positive given strong analyst support, though technical indicators show mixed signals with near-term resistance. Risks include consumer sentiment erosion and inflation impacts on discretionary spending. Upside potential hinges on sustained economic growth and sector outperformance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Consumer Discretionary Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: retail; hotels, restaurants and leisure; textiles, apparel and luxury goods; household durables; automobiles; auto components; distributors; leisure products; and diversified consumer services. It is non-diversified.
Read more on XLY →
